ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Bayer Schering Pharma will invest nearly $130 million in a new R&D center in Beijing over the next five years. "We are continuously increasing our presence in the Asia-Pacific region, where China is our key growth driver," company Chairman Andreas Fibig says. "In our new R&D center in Beijing, we will establish a world-class R&D team, extending our global R&D expertise and capabilities." China is the third-largest market worldwide for Bayer, and it will become the third country, after Germany and the U.S., to host a global R&D center for Bayer's pharma operations. Bayer also is in advanced discussions with Tsinghua University to establish a partnership focused on discovery of new disease targets.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter